Diagnoses transplanted at Cleveland Clinic include the blood and marrow cancers and other cancers:
- Aplastic Anemia
- Hodgkin Lymphoma
- Leukemia (all types)
- Multiple Myeloma
- Myelodysplastic Syndromes
- Non-Hodgkin Lymphoma
- Testicular Cancer
The Program offers multiple blood and marrow transplant options and utilizes various hematopoietic progenitor cell sources to fit the clinical need of the patient and the availability of the donor. Autologous, ablative & non-myeloablative (“mini”) allogeneic transplants, and tandem transplants are all potential treatments for cancer. Hematopoietic progenitor cell sources can be from blood and marrow, peripheral blood stem cells or umbilical cord blood.
Treating Blood & Marrow Cancers and More
Many patients who are seen at Cleveland Clinic have advanced forms of leukemia, lymphoma or other blood and marrow cancers that have failed numerous therapies making them high risk. Multiple cord blood protocols and the increased ability to use mismatched unrelated hematopoietic progenitor cells through stem cell manipulation offers these patients without potential treatment options a chance for a cure.
Allogen Laboratories at Cleveland Clinic have specialized, dedicated members of their team to work with the BMT physicians and nurse coordinators in searching and determining the best potential donor for patients with cancer. The Program utilizes all national and international stem cell and cord blood registries.